---
title: "Pomerantz LLP Announces Class Action Litigation Filing Against Savara Inc. – SVRA"
description: "Pomerantz LLP has filed a class action lawsuit against Savara Inc. and certain officers in the U.S. District Court for the Eastern District of Pennsylvania. The lawsuit, covering the period from March"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263859650.md"
published_at: "2025-11-01T15:00:02.000Z"
---

# Pomerantz LLP Announces Class Action Litigation Filing Against Savara Inc. – SVRA

> Pomerantz LLP has filed a class action lawsuit against Savara Inc. and certain officers in the U.S. District Court for the Eastern District of Pennsylvania. The lawsuit, covering the period from March 7, 2024, to May 23, 2025, alleges violations of federal securities laws related to misleading statements about the company's lead product candidate, MOLBREEVI. Following a refusal to file letter from the FDA regarding the Biologics License Application for MOLBREEVI, analysts have revised their price target for Savara, indicating potential financial difficulties ahead.

NEW YORK CITY, NY / ACCESS Newswire / November 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Savara Inc. ("Savara" or the "Company") and certain officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 25-cv-05147, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Savara securities between March 7, 2024 and May 23, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Savara securities during the Class Period, you have until November 7, 2025, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

\[Click here for information about joining the class action\]

Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The Company's lead product candidate is MOLBREEVI (also referred to as "molgramostim"), an inhaled granulocyte-macrophage colony-stimulating factor. MOLBREEVI is in a Phase 3 IMPALA-2 pivotal clinical trial for the treatment of autoimmune pulmonary alveolar proteinosis ("aPAP"), a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Savara has consistently represented that, based on investments in MOLBREEVI and its purported "track record of strong fiscal discipline," the Company is "sufficiently capitalized" as early as through 2026 and as late as into the second half of 2027.

In December 2024, Savara began a rolling submission of a Biologics License Application ("BLA")-*i.e.*, a submission requesting approval to distribute a biologic product across state lines-to the United States ("U.S.") Food and Drug Administration ("FDA") for MOLBREEVI for the potential treatment of aPAP (the "MOLBREEVI BLA"). In a press release announcing the submission, the Company touted that, "given the positive results of the pivotal, Phase 3 IMPALA-2 trial, we believe MOLBREEVI demonstrates a favorable benefit-risk profile and could fundamentally change the way aPAP is treated," and that "initiation of the \[MOLBREEVI\] BLA is an important milestone in potentially addressing the unmet need in aPAP, for which there are no approved medicines in the U.S. and Europe." Moreover, Savara represented that it "expect\[ed\] to complete the submission of the rolling \[MOLBREEVI\] BLA by the end of \[the first quarter of\] 2025."

To obtain FDA approval of the MOLBREEVI BLA, Savara must submit, among other things, information regarding MOLBREEVI's chemistry, manufacturing, and controls ("CMC"). Specifically, the CMC section of a BLA must provide a detailed account of a product's manufacturing process-including process validation runs, stability testing, and analytical method validation-and detailed descriptions of facilities, equipment, and quality control procedures.

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the MOLBREEVI BLA lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) the foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv) the delay in MOLBREEVI's regulatory approval increased the likelihood that the Company would need to raise additional capital; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On May 27, 2025, Savara issued a press release "announcing that the Company received \[a refusal to file\] letter from the FDA for the \[MOLBREEVI BLA\] as a therapy to treat patients with \[aPap\]." Specifically, Savara revealed that "\[u\] pon preliminary review, the FDA determined that the \[MOLBREEVI BLA\] was not sufficiently complete to permit substantive review and requested additional data related to Chemistry, Manufacturing, and Controls (CMC)."

Market analysts were quick to comment on the Company's announcement. For example, on May 27, 2025, Guggenheim published a report (the "Guggenheim Report") revising its price target for Savara to $8.00, down from the previous $9.00. Guggenheim stated that it "do\[es\] not expect Savara to be profitable on a continuing basis until 2028 and expect\[s\] the company may raise additional capital, potentially through a secondary stock offering that could dilute the holdings of current investors." In addition, the Guggenheim Report noted that the "CMC Delay Could Lead to Change in Molbreevi Manufacturing Strategy," predicting a delayed market launch sometime in early 2027, a year later than initially expected.

On this news, Savara's stock price fell $0.90 per share, or 31.69%, to close at $1.94 per share on May 27, 2025.

Then, after the end of the Class Period, on August 13, 2025, Savara issued a press release announcing the Company's financial results for the second quarter of 2025. Among other things, the press release revealed that, contrary to the Company's prior representations that it would complete its rolling submission of the MOLBREEVI BLA in the first quarter of 2025, Savara now "plan\[s\] to resubmit the \[MOLBREEVI\] BLA in December \[2025\]."

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

**SOURCE:** Pomerantz LLP

View the original press release on ACCESS Newswire

### Related Stocks

- [SVRA.US - Savara](https://longbridge.com/en/quote/SVRA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 活躍股票：Savaria Corporation | 上午 09:47（東部標準時間）- Savaria Corporation：已完成對 Baxter Residential Elevators, LLC 的幾乎所有資產的收購，該公司是位於德克薩斯州弗里斯科的領先家用電梯和升降機經銷商及安裝 | [Link](https://longbridge.com/en/news/275335167.md) |
| Savaria 收購 Baxter 住宅電梯以擴大在德克薩斯州的業務 | Savaria Corporation 已收購位於德克薩斯州的家用電梯經銷商和安裝商 Baxter Residential Elevators，增強了其在達拉斯市場的存在。Baxter 成立於 2004 年，預計在 2025 年產生約 40 | [Link](https://longbridge.com/en/news/275320297.md) |
| HelloNation 在文章中解釋了被捕後會發生什麼，並介紹了匹茲堡律師 Frank Walker | 最近一篇關於 HelloNation 的文章，介紹了匹茲堡律師 Frank Walker 所闡述的賓夕法尼亞州的逮捕流程，詳細説明了從登記到提審和初步聽證的各個步驟。文章強調了在這些階段獲得法律代表的重要性，因為擁有律師可以顯著影響保釋決定 | [Link](https://longbridge.com/en/news/276079705.md) |
| 艾仕得塗料系統公佈第四季度業績以及創紀錄的 2025 年收益 | 費城，賓夕法尼亞州 — 艾仕得塗料系統（Axalta Coating Systems Ltd.，紐約證券交易所代碼：AXTA）於 2 月 10 日公佈了 2025 年第四季度和全年財務業績，儘管銷售額下降，但仍報告了創紀錄的年度調整後收益和 | [Link](https://longbridge.com/en/news/276070886.md) |
| 1st Colonial Bancorp, Inc. 獲得股東批准與 Mid Penn Bancorp, Inc.合併 \| MPB 股票新聞 | 1st Colonial Bancorp, Inc. 的股東在 2026 年 2 月 11 日舉行的特別會議上批准了與賓州中部銀行的合併。超過 99% 的投票支持合併提案，這將增強賓州中部銀行在大費城地區的影響力，並擴大其在東南賓夕法尼亞州 | [Link](https://longbridge.com/en/news/275667667.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.